Surgery Partners, Inc.
NASDAQ:SGRYMedical - Care Facilities
+$0.06 today
- Market cap
- $3.53B
- Beta
- 1.95
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.59
Volume 3.24M
Average 1.36M
SGRY Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Surgery Partners, Inc.NASDAQ: SGRY
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue grows, but more slowly than its trailing trend
Q3 FY2026 cost of revenue of $630.3M rose 0.7% year over year, behind the +6.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 4.3% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.
Context
- Cost of revenue amounted to 76.9% of revenue in FY2025, up 0.8 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.7% toward the trailing-twelve-month pace of +6.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 2.54B USD
- Year-over-year change
- +7.4%
- 4-year CAGR
- +10.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.54B | +7.4% |
| FY2024 | 2024-12-31 | 2.37B | +13.0% |
| FY2023 | 2023-12-31 | 2.1B | +6.7% |
| FY2022 | 2022-12-31 | 1.96B | +13.3% |
| FY2021 | 2021-12-31 | 1.73B | — |
Cost of Revenue vs competitors
How SGRY compares with its peers on the latest reported figures
- SGRY's LTM Sep 2026 cost of revenue of $2.65B is the 5th highest of the 7 companies compared; the peer median is $6.59B.
- Its year-over-year change of +6.0% is the 6th highest of 7, against a peer median of +39.8%.
- Cost of revenue amounts to 78.9% of revenue for SGRY, versus a peer median of 51.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.89B | +30.1% | +6.1% | 71.6% | |
| LTM Jun 2026 | $15.95B | +100.3% | -32.2% | 73.1% | |
| LTM Mar 2026 | $9.96B | +35.0% | +16.0% | 46.3% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $3.23B | +127.0% | -45.4% | 50.3% |
| LTM Sep 2026 | $2.65B | +6.0% | +9.0% | 78.9% | |
| LTM Jun 2026 | $1.69B | +4.3% | +4.0% | 9.3% | |
| LTM Mar 2026 | $462.28M | +44.5% | +28.3% | 52.5% | |
| Peer median (excluding SGRY) | $6.59B | +39.8% | +5.0% | 51.4% | |
Competitors are the stored peer set for SGRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.23B | 2.54B | 2.74B | 3.11B | 3.31B |
| Cost of Revenue | 1.73B | 1.96B | 2.1B | 2.37B | 2.54B |
| Gross Profit | 491.4M | 574.9M | 647.5M | 745.6M | 765M |
| Gross Margin | 22.1% | 22.6% | 23.6% | 23.9% | 23.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 104M | 102.2M | 120.9M | 138.7M | 522.7M |
| Operating Expenses | 189.2M | 229.7M | 319.5M | 396.8M | 375.5M |
| Depreciation & Amortization | 98.8M | 114.8M | 118.1M | 152.6M | 176M |
| EBITDA | 401M | 460M | 446.1M | 501.4M | 565.5M |
| EBITDA Margin | 18.0% | 18.1% | 16.3% | 16.1% | 17.1% |
| Operating Income | 302.2M | 345.2M | 328M | 348.8M | 389.5M |
| Operating Margin | 13.6% | 13.6% | 12.0% | 11.2% | 11.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 221M | 234.9M | 193M | 201.7M | 272.6M |
| Other Income / Expenses | (221M) | (234.9M) | (193M) | (201.7M) | (272.6M) |
| Income Before Tax | 81.2M | 110.3M | 135M | 147.1M | 116.9M |
| Pre-Tax Margin | 3.6% | 4.3% | 4.9% | 4.7% | 3.5% |
| Income Tax Expense | 10.5M | 23.3M | (300K) | 134.6M | 18M |
| Net Income | (70.9M) | (54.6M) | (11.9M) | (168.1M) | (77.9M) |
| Net Margin | -3.2% | -2.2% | -0.4% | -5.4% | -2.4% |
| EPS (Basic) | (1.12) | (0.59) | (0.09) | (1.33) | (0.61) |
| EPS (Diluted) | (1.12) | (0.59) | (0.09) | (1.33) | (0.61) |
| Weighted Avg Shares | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M |
| Weighted Avg Shares (Diluted) | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M |
Surgery Partners, Inc.
NASDAQ:SGRY
Intrinsic Alpha fair value
Locked
Current Price
$26.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.